Do adrenergically active drugs have a role in the first-line treatment of attention-deficit/hyperactivity disorder?

@article{Hazell2005DoAA,
  title={Do adrenergically active drugs have a role in the first-line treatment of attention-deficit/hyperactivity disorder?},
  author={Philip L Hazell},
  journal={Expert Opinion on Pharmacotherapy},
  year={2005},
  volume={6},
  pages={1989 - 1998}
}
  • P. Hazell
  • Published 1 October 2005
  • Psychology, Biology, Medicine
  • Expert Opinion on Pharmacotherapy
Adrenergically active drugs used for the treatment of attention-deficit/hyperactivity disorder (ADHD) include the α-agonists, monoamine oxidase inhibitors, tricyclics and the selective noradrenergic re-uptake inhibitors. In addition to a longer duration of treatment effect than the predominantly dopaminergic psychostimulant drugs, a theoretical advantage of the adrenergically active drugs is a lesser tendency to aggravate common comorbidities of ADHD, such as anxiety, obsessionality, depression… 
2 Citations

Chronic Disorders in Children and Adolescents

Chronic disorders in children and adolescents , Chronic disorders in children and adolescents , کتابخانه دیجیتال جندی شاپور اهواز

References

SHOWING 1-10 OF 73 REFERENCES

Non-Stimulant Treatment of Attention-Deficit/Hyperactivity Disorder

TLDR
Clinical guidelines for each of these agents, as well as their use in combination with stimulants in comorbid conditions, will be discussed.

Novel treatments for attention-deficit/hyperactivity disorder in children.

TLDR
Atomoxetine, which is being developed for ADHD, reduces symptoms of ADHD without exacerbating comorbid conditions and is associated with only minor side effects, including subtle changes in blood pressure and heart rate.

Atomoxetine hydrochloride for the treatment of attention-deficit/hyperactivity disorder.

A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder.

TLDR
Treatment with desipramine was well tolerated and was associated with robust clinically significant reductions in tic and ADHD symptoms in children and adolescents with chronic tic disorders and ADHD diagnoses.

Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder.

TLDR
Two studies early in its development confirmed that atomoxetine, a specific and selective inhibitor of noradrenergic uptake, was effective for the treatment of children with ADHD and was found to be well tolerated.

Treatment of hyperactive children with monoamine oxidase inhibitors. I. Clinical efficacy.

TLDR
Findings of equivalent efficacy of MAOIs in ADD are in contrast to previous studies with neurotransmitter system selective agents, which showed only weak effects, and suggest that multiple neurotransmitter alterations may be required for stimulant drug effects in ADD.

Pharmacological management of attention-deficit hyperactivity disorder

TLDR
There is a need for additional direct comparisons between the longer-acting agents to effectively guide the practicing clinician in selecting an agent for the treatment of ADHD.

Venlafaxine in adults with attention-deficit/hyperactivity disorder: an open clinical trial.

TLDR
Venlafaxine may be a promising agent for the treatment of ADHD in adults and controlled clinical trials are needed to further examine this issue.

New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder

TLDR
The newly approved resolved enantiomer product d-MPH is now available in an IR formulation, and when administered at one-half the dose to that of the racemate, is purported to produce a longer duration of clinical effect, despite essentially identical pharmacokinetics.

Safety profile of atomoxetine in the treatment of children and adolescents with ADHD.

TLDR
Cardiac effects and effects on weight, height, and metabolism that are related to treatment of ADHD with atomoxetine in children and adolescents are discussed.
...